Investors
-
Share price information
ZEAL (COP)
321.40DKKZealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL. Access investor information including full share price in DKK plus investor tools.
More Stock information -
Annual Report 2025
-
Corporate presentation
Catch up on our past events
View the webcasts and documents from our past events here
71%
of our operating expenditure focused on R&D in 2025
20
analysts covering Zealand Pharma
71.5m
shares outstanding as of December 31, 2025
500+
employees in Denmark and the United States
Financial calendar
See all financial events-
Q3 Financial Results / Interim Report Third Quarter 2026
Annual Report 2025
Latest annual report
Read Zealand Pharma's annual report for 2025.
Latest news
Newsroom-
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
READ MORE -
Zealand Pharma Announces Financial Results for the First Half of 2026
READ MORE -
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
READ MORE -
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
READ MORE
Stay up-to-date with the latest news from Zealand
Sign up to receive press releases and important company announcements directly to your inbox
-
Corporate governance
At Zealand Pharma, our corporate governance structure aims to support long-term financial performance, meet the obligations of our stakeholders, and create value for shareholders and society.
-
Annual general meeting
The Annual General Meeting for 2026 was held on March 26th, 2026 at 15:00 CET. Find additional information on the AGM page.
-
Analyst coverage
Zealand Pharma is currently covered by 15 analysts and financial institutions across the U.S and Europe.
Safety, tolerability, and clinical effects of ZP8396, an amylin analog
Featured publications
Results from a 16-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.
An innovative R&D pipeline
More investor information
Investor relations policy
We are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner.
Prospectus
Read our latest prospectus and prospectus summary from April 3, 2023.
Investor and Media contacts
